Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer

Thomas J. Herzog, Sandro Pignata, Sharad A. Ghamande, Maria Jesús Rubio, Keiichi Fujiwara, Christof Vulsteke, Deborah K. Armstrong, Jalid Sehouli, Robert L. Coleman, Hani Gabra, Giovanni Scambia, Bradley J. Monk, José A. Arranz, Kimio Ushijima, Rabbie Hanna, Claudio Zamagni, Robert M. Wenham, Antionio González-Martín, Brian Slomovitz, Yan JiaLisa Ramsay, Krishnansu S. Tewari, Susan C. Weil, Ignace B. Vergote

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Fingerprint

Dive into the research topics of 'Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences